-+ 0.00%
-+ 0.00%
-+ 0.00%

BOEHRINGER INGELHEIM: PHASE 1B STUDY TO EVALUATE COMBINATION OF ZONGERTINIB AND ZANIDATAMAB IN HER2-POSITIVE BREAST CANCER PATIENTS

Reuters·01/12/2026 12:05:04

Please log in to view news